Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8482896 | 0.81 | PTGS2 (0.56) | PTGS2POLBKMT2AL3MBTL1PTPRC | |
| SCHEMBL78629 | 0.77 | PTGS2 (0.54) | PTGS2POLBKMT2AL3MBTL1PTPRC | |
| SCHEMBL13402185 | 0.76 | PTGS2 (0.41) | PTGS2 | |
| SCHEMBL8648034 | 0.75 | PTGS2 (0.51) | PTGS2POLBKMT2AL3MBTL1PTPRC | |
| SCHEMBL8650686 | 0.74 | PTGS2 (0.54) | PTGS2POLBKMT2AL3MBTL1PTPRC | |
| SCHEMBL28842455 | 0.74 | TSHR (0.46) | KMT2A | |
| SCHEMBL1983875 | 0.74 | TSHR (0.46) | KMT2A | |
| SCHEMBL8530900 | 0.73 | HTT (0.37) | L3MBTL1 | |
| Hydrochloric Acid SCHEMBL29712425 | 0.73 | L3MBTL1 (0.41) | L3MBTL1 | |
| SCHEMBL9706821 | 0.72 | L3MBTL1 (0.38) | KMT2AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313736-B1 | CONDENSED PYRAZINDIONE DERIVATIVES AS INHIBITORS OF PDE5 | LILLY ICOS LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-6903099-B2 | Condensed pyrazindione derivatives | LILLY ICOS LLC (US) | 2005-06-07 | — | — | US | disclosed |
| US-20030181457-A1 | Chemical compounds | LILLY ICOS LLC | 2003-09-25 | — | — | US | disclosed |
| EP-1313736-A2 | CONDENSED PYRAZINDIONE DERIVATIVES | Lilly Icos LLC (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002000657-A2 | CONDENSED PYRAZINDIONE DERIVATIVES | LILLY ICOS LLC (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181457-A1 | Chemical compounds | ABCG2, SDHA, CYP11B1 | PTGS2 1729/4885POLB 863/4885KMT2A 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.